Curevac Nv Stock Analysis
| CVAC Stock | USD 2.45 0.12 4.67% |
CureVac NV is undervalued with Real Value of 5.72 and Target Price of 14.91. The main objective of CureVac NV stock analysis is to determine its intrinsic value, which is an estimate of what CureVac NV is worth, separate from its market price. There are two main types of CureVac NV's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect CureVac NV's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of CureVac NV's stock to identify patterns and trends that may indicate its future price movements.
The CureVac NV stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. CureVac NV is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. CureVac Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and CureVac NV's ongoing operational relationships across important fundamental and technical indicators.
CureVac |
CureVac Stock Analysis Notes
About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.01. Some equities with similar Price to Book (P/B) outperform the market in the long run. CureVac NV has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 1.57. The firm had not issued any dividends in recent years. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 764 people. For more info on CureVac NV please contact LLM LLM at 49 7071 9883 0 or go to https://www.curevac.com.CureVac NV Quarterly Total Revenue |
|
CureVac NV Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. CureVac NV's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding CureVac NV or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| CureVac NV generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 42.88 M. Net Loss for the year was (302.3 M) with loss before overhead, payroll, taxes, and interest of (91.55 M). | |
| CureVac NV currently holds about 540.87 M in cash with (273.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 45.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: CureVac and MD Anderson partner on mRNA cancer vaccines |
CureVac NV Upcoming and Recent Events
Earnings reports are used by CureVac NV to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CureVac NV previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 23rd of April 2024 Upcoming Quarterly Report | View | |
| 4th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 23rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
CureVac Largest EPS Surprises
Earnings surprises can significantly impact CureVac NV's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-18 | 2022-06-30 | -0.26 | -0.31 | -0.05 | 19 | ||
2023-08-17 | 2023-06-30 | -0.24 | -0.3 | -0.06 | 25 | ||
2023-05-30 | 2023-03-31 | -0.34 | -0.27 | 0.07 | 20 |
CureVac Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CureVac NV is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CureVac NV backward and forwards among themselves. CureVac NV's institutional investor refers to the entity that pools money to purchase CureVac NV's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Junked Platinum Investment Management Ltd | 2023-12-31 | 497.9 K | Eversept Partners, Llc | 2023-12-31 | 496.9 K | Norges Bank | 2023-12-31 | 308.7 K | Credit Suisse First Boston (csfb) | 2023-12-31 | 303.9 K | Adage Capital Partners Gp Llc | 2023-12-31 | 248.4 K | Geode Capital Management, Llc | 2023-12-31 | 202 K | Swiss National Bank | 2023-12-31 | 198.5 K | Susquehanna International Group, Llp | 2023-12-31 | 178.2 K | Ubs Group Ag | 2023-12-31 | 131.9 K | Citadel Advisors Llc | 2023-09-30 | 3.1 M | Ra Capital Management, Llc | 2023-12-31 | 2.7 M |
CureVac Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 596.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CureVac NV's market, we take the total number of its shares issued and multiply it by CureVac NV's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.CureVac Profitablity
CureVac NV's profitability indicators refer to fundamental financial ratios that showcase CureVac NV's ability to generate income relative to its revenue or operating costs. If, let's say, CureVac NV is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, CureVac NV's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of CureVac NV's profitability requires more research than a typical breakdown of CureVac NV's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.42) | (0.40) |
Management Efficiency
CureVac NV has return on total asset (ROA) of (0.1803) % which means that it has lost $0.1803 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4926) %, meaning that it created substantial loss on money invested by shareholders. CureVac NV's management efficiency ratios could be used to measure how well CureVac NV manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.33. At present, CureVac NV's Fixed Asset Turnover is projected to increase slightly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.1, whereas Total Assets are forecasted to decline to about 833 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.54 | 1.90 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 2.39 | 1.83 | |
| Enterprise Value Over EBITDA | (2.48) | (2.60) | |
| Price Book Value Ratio | 2.30 | 2.19 | |
| Enterprise Value Multiple | (2.48) | (2.60) | |
| Price Fair Value | 2.30 | 2.19 | |
| Enterprise Value | 707.2 M | 671.8 M |
The analysis of CureVac NV's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze CureVac NV's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of CureVac Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 2.505 |
Technical Drivers
As of the 18th of April 2024, CureVac NV shows the Risk Adjusted Performance of (0.12), mean deviation of 2.12, and Standard Deviation of 2.78. CureVac NV technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze thirteen technical drivers for CureVac NV, which can be compared to its peers. Please confirm CureVac NV maximum drawdown, as well as the relationship between the potential upside and kurtosis to decide if CureVac NV is priced correctly, providing market reflects its regular price of 2.45 per share. Please also double-check CureVac NV jensen alpha, which is currently at (0.65) to validate the company can sustain itself at a future point.CureVac NV Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. CureVac NV middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for CureVac NV. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
CureVac NV Predictive Daily Indicators
CureVac NV intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of CureVac NV stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
CureVac NV Corporate Filings
6K | 16th of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 4th of April 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 6th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
6K | 17th of January 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 5th of January 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 19th of December 2023 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 14th of November 2023 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
CureVac NV Forecast Models
CureVac NV's time-series forecasting models are one of many CureVac NV's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CureVac NV's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About CureVac Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how CureVac NV prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CureVac shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as CureVac NV. By using and applying CureVac Stock analysis, traders can create a robust methodology for identifying CureVac entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (3.33) | (3.49) | |
| Operating Profit Margin | (3.33) | (3.50) | |
| Net Loss | (3.32) | (3.49) | |
| Gross Profit Margin | (1.99) | (1.89) |
Current CureVac Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CureVac analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CureVac analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 14.91 | Buy | 7 | Odds |
Most CureVac analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CureVac stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CureVac NV, talking to its executives and customers, or listening to CureVac conference calls.
CureVac Stock Analysis Indicators
CureVac NV stock analysis indicators help investors evaluate how CureVac NV stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CureVac NV shares will generate the highest return on investment. By understating and applying CureVac NV stock analysis, traders can identify CureVac NV position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 540.9 M | |
| Common Stock Shares Outstanding | 189.1 M | |
| Total Stockholder Equity | 533.3 M | |
| Tax Provision | 67 K | |
| Property Plant And Equipment Net | 241.7 M | |
| Cash And Short Term Investments | 500.3 M | |
| Cash | 495.8 M | |
| Accounts Payable | 68.2 M | |
| Net Debt | -453.7 M | |
| 50 Day M A | 3.2293 | |
| Total Current Liabilities | 156.2 M | |
| Non Current Assets Total | 276.4 M | |
| Forward Price Earnings | 9.1659 | |
| Non Currrent Assets Other | 1.7 M | |
| Stock Based Compensation | 9 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share 0.201 | Quarterly Revenue Growth 0.47 | Return On Assets (0.18) | Return On Equity (0.49) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.